Ser1535
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser1535 - CHD-4 (human)

Site Information
KKMSQPGsPSPKTPT    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: CHD‑4 (mouse): S1528, CHD‑4 (rat): S1528, CHD‑4 iso3 (mouse): S1535, CHD‑4 iso4 (human): S1528
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (3, 4, 6, 7, 8, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)
Disease tissue studied: cervical cancer (22), cervical adenocarcinoma (22), leukemia (34, 35, 36), chronic myelogenous leukemia (34, 35, 36)
Relevant cell line - cell type - tissue: 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] (15), 293 (epithelial) [AT1 (human), transfection] (14), A498 (renal) (18), DG75 (B lymphocyte) (13), Flp-In T-Rex-293 (epithelial) (4), Flp-In T-Rex-293 (epithelial) [PKD1 (human), genetic knockin] (4), GM00130 (B lymphocyte) (17), HeLa (cervical) (3, 10, 12, 23, 28, 29, 30, 32, 41), HeLa (cervical) [OGT (rat), transfection] (23), HeLa S3 (cervical) (22), HT-29 (intestinal) (40), HUES-7 ('stem, embryonic') (27), Jurkat (T lymphocyte) (6, 7, 8, 16, 19, 20, 24, 31, 37), K562 (erythroid) (3, 33, 34, 35, 36), leukocyte-blood (21), NCI-H1703 (squamous) (38, 39)

Controlled by
Treatments: nocodazole (22)



References

1

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

2

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

3

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

4

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

5

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

6

(2011) CST Curation Set: 12709; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation)
Curated Info

7

(2011) CST Curation Set: 12710; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation)
Curated Info

8

(2011) CST Curation Set: 11892; Year: 2011; SILAC: N; Biosample/Treatment: Jurkat(cell line)/calyculin & pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

9

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

10

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

11

Phanstiel DH, et al. (2011) Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nat Methods 8, 821-7
21983960   Curated Info

12

(2010) CST Curation Set: 10708; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/untreated; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXsP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

13

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

14

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

15

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

16

(2010) CST Curation Set: 9960; Year: 2010; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate & calyculin; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation)
Curated Info

17

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

18

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

19

(2010) CST Curation Set: 9252; Year: 2010; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate & calyculin; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

20

(2010) CST Curation Set: 8990; Year: 2010; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate & calyculin; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

21

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

22

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

23

Wang Z, et al. (2010) Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci Signal 3, ra2
20068230   Curated Info

24

(2009) CST Curation Set: 8039; Year: 2009; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate & calyculin; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

25

(2009) CST Curation Set: 7661; Year: 2009; SILAC: N; Biosample/Treatment: bone marrow(tissue)/untreated; Disease: acute myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

26

(2009) CST Curation Set: 7662; Year: 2009; SILAC: N; Biosample/Treatment: bone marrow(tissue)/untreated; Disease: acute myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

27

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

28

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

29

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

30

(2009) CST Curation Set: 6253; Year: 2009; SILAC: N; Biosample/Treatment: HeLa(cell line)/UV; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

31

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

32

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

33

(2008) CST Curation Set: 4605; Year: 2008; SILAC: N; Biosample/Treatment: K562(cell line)/untreated; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

34

(2008) CST Curation Set: 4390; Year: 2008; SILAC: N; Biosample/Treatment: K562(cell line)/untreated; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

35

(2008) CST Curation Set: 4394; Year: 2008; SILAC: N; Biosample/Treatment: K562(cell line)/untreated; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

36

(2007) CST Curation Set: 2723; Year: 2007; SILAC: N; Biosample/Treatment: K562(cell line)/normal; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

37

(2007) CST Curation Set: 2649; Year: 2007; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate & calyculin; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)XP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

38

(2006) CST Curation Set: 1664; Year: 2006; SILAC: N; Biosample/Treatment: NCI-H1703(cell line)/serum starved; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

39

(2006) CST Curation Set: 1665; Year: 2006; SILAC: N; Biosample/Treatment: NCI-H1703(cell line)/serum starved; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

40

(2005) CST Curation Set: 800; Year: 2005; SILAC: N; Biosample/Treatment: HT-29(cell line)/-; Disease: colorectal carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

41

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.